Journal of pediatric surgery · 2025
Respiratory Outcomes in Children Born With Esophageal Atresia With or Without Tracheoesophageal Fistula: A Retrospective Longitudinal Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Asemota Osamuyi, Shawyer Anna C, Iqbal Shaikh, Lum Min Suyin A, Keijzer Richard
Аннотация
BACKGROUND: The respiratory health of children born with esophageal atresia with or without tracheoesophageal fistula (EA/TEF) can be compromised.
PURPOSE: We aimed to study how respiratory outcomes in EA/TEF cases change with increasing age and over time.
METHODS: We performed a retrospective cohort study of children with EA/TEF treated in our centre from 1991 to 2022 and compared their respiratory outcomes to those of date-of-birth matched controls. Respiratory outcomes up to 2022 were identified using International Classification of Diseases codes (ICD-9). Odds ratios (OR), rate ratios (RaR) and Cox proportional hazard models were used to compare acute respiratory infections (ICD-9:460-466), asthma (ICD-9:493), bronchitis (ICD-9:490-491), influenza (ICD-9:487-488), and pneumonia (ICD-9:480-486) between cases and controls.
RESULTS: A total of 95 cases and 945 controls were included. Cases were more likely to have asthma (OR = 2.32, 95%CI = 1.51,3.58) and pneumonia (OR = 5.94, 95%CI = 2.37,3.65) compared to controls. Cases had more episodes of acute respiratory tract infections and bronchitis (RaR = 1.45, 95%CI = 1.32,1.58; RaR = 13.3, 95%CI = 11.2,15.9, respectively). Influenza was unaffected by EA/TEF status. By late adolescence, new or recurrent episodes of respiratory disorders were uncommon, except for acute respiratory tract infections which continued to recur more often in cases than controls into adulthood. EA/TEF survivors born in recent years experienced fewer respiratory complaints than those born in the remote past.
CONCLUSION: Although the respiratory outcomes of children with EA/TEF were worse than controls, survivors can expect improved pulmonary health as they approach maturity, and respiratory health is improving for the contemporaneous EA/TEF population.
LEVEL OF EVIDENCE: Prognostic, Level III.
PURPOSE: We aimed to study how respiratory outcomes in EA/TEF cases change with increasing age and over time.
METHODS: We performed a retrospective cohort study of children with EA/TEF treated in our centre from 1991 to 2022 and compared their respiratory outcomes to those of date-of-birth matched controls. Respiratory outcomes up to 2022 were identified using International Classification of Diseases codes (ICD-9). Odds ratios (OR), rate ratios (RaR) and Cox proportional hazard models were used to compare acute respiratory infections (ICD-9:460-466), asthma (ICD-9:493), bronchitis (ICD-9:490-491), influenza (ICD-9:487-488), and pneumonia (ICD-9:480-486) between cases and controls.
RESULTS: A total of 95 cases and 945 controls were included. Cases were more likely to have asthma (OR = 2.32, 95%CI = 1.51,3.58) and pneumonia (OR = 5.94, 95%CI = 2.37,3.65) compared to controls. Cases had more episodes of acute respiratory tract infections and bronchitis (RaR = 1.45, 95%CI = 1.32,1.58; RaR = 13.3, 95%CI = 11.2,15.9, respectively). Influenza was unaffected by EA/TEF status. By late adolescence, new or recurrent episodes of respiratory disorders were uncommon, except for acute respiratory tract infections which continued to recur more often in cases than controls into adulthood. EA/TEF survivors born in recent years experienced fewer respiratory complaints than those born in the remote past.
CONCLUSION: Although the respiratory outcomes of children with EA/TEF were worse than controls, survivors can expect improved pulmonary health as they approach maturity, and respiratory health is improving for the contemporaneous EA/TEF population.
LEVEL OF EVIDENCE: Prognostic, Level III.